GLP-1 Medications After Pregnancy: What Postpartum Moms Need to Know
GLP-1 medications are everywhere right now. Ozempic, Wegovy, Mounjaro, and Zepbound have changed the conversation around weight loss, diabetes, and obesity. So naturally, many women are wondering where these medications fit after pregnancy.
Can you start a GLP-1 postpartum? What if you’re breastfeeding? Could it affect your milk supply? And how much do we actually know about the long-term effects?
The answers are more complicated than a simple yes or no.
As both a registered nurse and a twin mom, this is one of those topics where I think it’s especially important to separate what current evidence tells us from what we simply don’t know yet. I also think it’s okay to admit when those are two very different things.
What Are GLP-1 Medications?
GLP-1 medications mimic a hormone involved in blood sugar regulation, digestion, and appetite. They can slow stomach emptying, help you feel full longer, and reduce appetite.
Some of the names you’ve probably heard include:
Ozempic and Wegovy: semaglutide
Mounjaro and Zepbound: tirzepatide
Saxenda and Victoza: liraglutide
Not all of these medications have the same FDA-approved uses. Some are approved for type 2 diabetes, some for chronic weight management, and tirzepatide acts on both GIP and GLP-1 receptors. That distinction matters, especially when we’re talking about medication decisions rather than simply “getting on Ozempic.”
Why GLP-1s Come Up So Often Postpartum
Pregnancy changes your body. Twin pregnancy can change it a lot.
You may leave the hospital having delivered two babies and still look pregnant. Your hormones are changing. You’re sleep deprived. You may be breastfeeding or pumping around the clock. You’re trying to recover while somehow keeping tiny humans alive.
And then the world starts talking about “getting your body back.”
GLP-1 medications can produce significant weight loss, so it’s understandable that postpartum women are interested in them. For some women, there may also be medical reasons to discuss one with a healthcare provider, including obesity or type 2 diabetes.
But postpartum isn’t just another season of life for your body. Recovery, nutrition, breastfeeding, future pregnancy plans, and your overall health all deserve to be part of that conversation.
Can You Take a GLP-1 After Pregnancy?
Potentially, yes. Simply being postpartum doesn’t automatically prevent someone from using a GLP-1 medication.
The bigger questions are whether you’re breastfeeding, why the medication is being prescribed, your current health and nutritional status, which medication you’re considering, and whether you plan to become pregnant again.
This is also where I would be careful with blanket statements online. “GLP-1s are safe postpartum” is too broad. “GLP-1s are dangerous postpartum” is too broad, too. There are individual decisions hiding underneath both statements.
What About GLP-1s While Breastfeeding?
This is where things get interesting because the evidence is changing.
For a long time, there was very little human lactation data for these medications. We now have some information, particularly for injectable semaglutide and tirzepatide, but we’re still talking about relatively small amounts of evidence.
Semaglutide While Breastfeeding
LactMed currently reports that injectable semaglutide was not detectable in breast milk samples from eight nursing mothers taking 0.25 to 1 mg weekly. No adverse effects were reported in their breastfed children.
That’s reassuring. But there’s an important second half to that sentence.
The children in that study were between 4 and 23 months old, were mixed-fed rather than exclusively breastfed, and exposure was followed for a relatively short period. We do not have large studies following babies exposed through breast milk over many years.
LactMed currently distinguishes injectable semaglutide from oral semaglutide. Some oral formulations contain an absorption enhancer that creates additional concerns, and LactMed recommends only injectable semaglutide during breastfeeding.
Tirzepatide While Breastfeeding
We now have some lactation information for tirzepatide as well. In a manufacturer study of 11 lactating women given a single 5 mg dose, tirzepatide was undetectable in 164 of 171 breast-milk samples. The total amount detected in the remaining samples was less than 0.02% of the maternal dose.
However, LactMed specifically notes an important limitation: this was a single-dose study, so it doesn’t fully represent the drug levels that might occur with regular weekly use over time.
LactMed’s current position is that needing tirzepatide is not, by itself, a reason to discontinue breastfeeding, while still recommending caution until more data are available, particularly when nursing a newborn or premature infant.
That’s a very different answer from either “absolutely safe” or “absolutely forbidden.”
What We Know vs. What We Don’t Know
This distinction matters to me.
Current evidence suggests that transfer of injectable semaglutide and tirzepatide into human milk may be very low. That’s useful information, and I don’t think we should ignore reassuring evidence simply because it doesn’t fit a more cautious viewpoint.
But low or undetectable levels in breast milk are not the same thing as having decades of long-term safety data.
We still need more information about things like:
Long-term outcomes in breastfed children
Use during exclusive breastfeeding
Exposure in newborn and premature babies
Effects of prolonged maternal use during lactation
Potential effects on milk production
How significant maternal appetite suppression may affect postpartum nutrition
LactMed currently states that relevant published information about the effects of semaglutide and tirzepatide on milk production is lacking. That uncertainty deserves to be acknowledged without turning uncertainty itself into evidence of harm.
Could a GLP-1 Affect Milk Supply?
We don’t currently have good evidence showing exactly how GLP-1 medications affect milk production.
But there’s another piece of this conversation that isn’t just about how much medication gets into the milk. Mom still has to eat and drink enough to support her own body.
GLP-1 medications can significantly reduce appetite and commonly cause gastrointestinal side effects. A postpartum woman who is breastfeeding is already using additional energy and nutrients to produce milk.
That doesn’t automatically mean a GLP-1 will decrease someone’s milk supply. It does mean that nutrition, hydration, weight-loss rate, and milk production deserve attention if a breastfeeding mother and her healthcare provider decide that a GLP-1 is appropriate.
This may be particularly important in the early postpartum period, when milk supply is still being established.
Newborns and Preemies Deserve Extra Consideration
This is especially relevant to Twin Mom Club because twins are more likely to arrive early.
The breastfeeding evidence we have should not automatically be applied equally to a healthy older baby, a newborn, and a premature infant. LactMed specifically recommends additional caution with tirzepatide and other GLP-1 medications when breastfeeding a newborn or preterm infant because the available information remains limited.
If you’re exclusively breastfeeding premature newborn twins, that’s a very different situation from occasionally nursing healthy 18-month-old toddlers. Those details matter.
What If You Want Another Baby?
This needs to be part of the postpartum conversation too.
If another pregnancy may be in your future, tell your healthcare provider before starting a GLP-1. These medications generally aren’t used for weight loss during pregnancy, and some need to be stopped well before conception because they remain in the body for a significant amount of time.
For example, current Wegovy prescribing information says semaglutide should be discontinued at least two months before a planned pregnancy when it is being used for weight reduction or cardiovascular risk reduction. So if you’re thinking about trying for another baby soon, your timeline matters.
My RN + Twin Mom Perspective
This is one of those areas where my personal comfort level is more cautious than simply saying, “The medication wasn’t detected in breast milk, so we’re good.”
Eight mothers in a semaglutide study is encouraging evidence. It isn’t enough evidence to make me personally feel like every question has been answered. And I think those two thoughts can exist together.
I don’t believe it’s responsible to say that GLP-1 medications are going to be proven harmful in the long run when we don’t have evidence showing that. But I also don’t think “we haven’t found harm” should automatically become “we know there are no long-term risks.”
If I were making this decision while breastfeeding, I would want to talk through how old my babies were, whether they were premature, how much breast milk they were receiving, why I wanted or needed the medication, how my milk supply was doing, my nutritional intake, and whether waiting was a reasonable option for me.
Another mom may look at the same evidence with her healthcare provider and make a different decision. That’s what informed decision-making is supposed to look like.
Questions to Ask Your Healthcare Provider
If you’re considering a GLP-1 postpartum, these are good questions to bring with you:
Why are you recommending this medication for me?
Which GLP-1 medication would you recommend and why?
What evidence do we have about this specific medication during breastfeeding?
Does my baby’s age or prematurity change your recommendation?
Could waiting until my baby is older or weaned make sense for me?
How should I make sure I’m eating enough while breastfeeding?
Should I monitor my milk supply or my baby’s growth differently?
What side effects should make me contact you?
How long would I need to stop this medication before trying to become pregnant again?
You deserve more than a yes-or-no answer.
Twin Mom Tip
If you’re considering a GLP-1 while breastfeeding twins, tell your prescriber exactly what feeding looks like in your house.
“I’m breastfeeding” could mean exclusively nursing two premature newborns eight to twelve times a day. It could also mean nursing two toddlers once before bed. Those are not the same exposure or nutritional situation, and your provider needs the full picture.
Frequently Asked Questions
Can I take Ozempic while breastfeeding?
Current LactMed information is reassuring for injectable semaglutide, which was not detectable in milk in a small study of eight mothers. However, the study was small, the children were older and mixed-fed, and long-term data remain limited. This is a decision to make with your healthcare provider.
Can I take Wegovy while breastfeeding?
Wegovy contains semaglutide, so the available lactation evidence about injectable semaglutide is relevant. Your provider should weigh the available evidence, your reason for treatment, your baby’s age and health, and your individual situation.
Can I take Mounjaro or Zepbound while breastfeeding?
Both contain tirzepatide. Current evidence suggests that very little tirzepatide enters breast milk, but the human data remain limited. LactMed recommends caution, particularly with newborn or premature infants.
Will a GLP-1 decrease my milk supply?
We don’t currently have enough published evidence to say exactly how semaglutide or tirzepatide affects milk production. Because these medications can significantly suppress appetite, maternal nutrition and hydration are also important considerations during lactation.
Should I stop breastfeeding so I can start a GLP-1?
That’s an individualized medical decision. Current LactMed guidance does not say that every mother requiring injectable semaglutide or tirzepatide must stop breastfeeding. Your baby’s age and health, your medical needs, the specific medication, and your own preferences should all be considered.
The Bottom Line
GLP-1 medications after pregnancy aren’t a simple yes or no.
We have emerging evidence that is reassuring about the amount of injectable semaglutide and tirzepatide reaching breast milk. We also have significant gaps in our knowledge, especially when it comes to long-term exposure, newborns, premature babies, exclusive breastfeeding, and milk production.
We shouldn’t turn those gaps into proof that GLP-1s are dangerous. But we shouldn’t pretend those gaps don’t exist either.
Talk with your healthcare provider about your medication, your health, your baby or babies, your feeding situation, and your future pregnancy plans. You can respect the evidence and still ask hard questions.
References
National Library of Medicine, Drugs and Lactation Database (LactMed). Semaglutide. Updated August 15, 2026.
National Library of Medicine, Drugs and Lactation Database (LactMed). Tirzepatide. Updated August 15, 2026.
National Library of Medicine, Drugs and Lactation Database (LactMed). Liraglutide. Updated August 15, 2026.
U.S. Food and Drug Administration. Wegovy (semaglutide) Prescribing Information.
U.S. Food and Drug Administration. Zepbound (tirzepatide) Prescribing Information.
Medical Disclaimer
This article is for educational purposes only and should not replace individualized medical advice. Decisions about GLP-1 medications during the postpartum period or while breastfeeding should be made with a qualified healthcare professional who knows your medical history, medication needs, and your baby’s health.
